DAY 8

Perimenopause & Hormones
Symptoms, MHT, Bones, Body Composition

2026-05-30 · BigCat's Vitality Protocol
Evidence base: NAMS 2022 Position Statement + WHI re-analysis (Manson 2017) + ELITE/KEEPS RCTs + SWAN cohort. Emphasizes the "timing hypothesis" and individualized decisions.
SUB · Endocrine transition / Symptomatology
Perimenopause — A 4-to-10-Year Transition, Not a Day
BOTTOM LINE
Perimenopause is a 4–10 year window of hormonal turbulence before final menses, starting on average at age 45, with over 100 documented symptoms. A single FSH draw cannot diagnose it — diagnosis rests on cycle changes and symptom patterns.
EVIDENCE LEVEL
Large cohort: SWAN (Avis 2015, JAMA Intern Med, n=3302, 17-year follow-up) showed vasomotor symptoms (VMS: hot flashes / night sweats) lasted a median of 7.4 years, longer in Black women (10 years), shorter in Asian women. The STRAW+10 consensus (Harlow 2012) stages the transition: early (cycle variability ≥7 days) → late (≥60-day amenorrhea) → postmenopause.
SCIENCE + MECHANISM
Follicle count drops sharply after age 35; granulosa cells become erratic in FSH response, so estrogen swings wildly first (not a steady decline), while progesterone falls earliest. This "roller-coaster" pattern — not a smooth taper — is the core mechanism behind simultaneous sleep, mood, and VMS collapse. Hypothalamic thermoregulatory thresholds narrow (KNDy neurons become hypersensitive), driving hot flashes. Asian populations reach natural menopause around 49–50, 1–2 years earlier than Western averages.
VISUALIZATION: STRAW+10 stages and symptom trajectory
Stages and symptom intensity (x-axis: years relative to FMP) Early transition -5y Late transition -2y FMP Postmenopause VMS rising peak gradual decline Cycle variabilitySkipped / long cyclesVMS median 7.4 y
Source: STRAW+10 (Harlow 2012) + SWAN (Avis 2015). FMP = final menstrual period.
PROTOCOL
• Track symptoms for 3 months: use the Greene Climacteric Scale or a simple journal — hot-flash count, sleep quality, mood, cycle length
• Key bloodwork (early follicular phase, fasted morning): TSH, ferritin, vitamin D, HbA1c, fasting insulin, ApoB, CMP — don't just check FSH, a single value is non-diagnostic
• Clinician selection: bring your log to a NAMS-certified provider (NCMP); general gynecologists often aren't fluent in modern MHT evidence
• Non-hormonal first-line: CBT for menopause (MENOS RCT), Fezolinetant (KNDy antagonist, FDA-approved 2023), low-dose SSRIs
FEMALE-SPECIFIC + MYTHS
"Sudden anxiety / depression" is often misdiagnosed as a purely psychiatric issue. Perimenopause is a depression risk window (OR ~2); mechanism is estrogen fluctuation affecting 5-HT/GABA. Rule out hormonal contribution before stacking antidepressants.
Myth 1: "Regular periods means I'm not in perimenopause" — VMS and mood symptoms often begin while cycles still look normal.
Myth 2: "Wait until symptoms are severe" — missing the early hormonal window (<60 yr / within 10 yr of menopause) sharply reduces benefit.
THIS WEEK + REFLECTION
THIS WEEK
Download the Balance app or build a simple spreadsheet. For 14 days log: hot-flash count, night wakings, mood (1–10), and cycle day. Three months from now, this log is the best data you can bring to a clinician.

Reflection: Why is a physiological transition that affects 50% of the population for ~7 years on average so absent from mainstream medical education?
SUB · MHT / Timing hypothesis
Modern MHT — The 20-Year Detour After WHI
BOTTOM LINE
Started before age 60 or within 10 years of menopause, MHT produces favorable benefit/risk for symptom relief, bone protection, and likely cardiovascular outcomes. Preferred regimen: transdermal estradiol + micronized progesterone, not the 1990s oral conjugated equine estrogens + MPA.
EVIDENCE LEVEL
RCT: ELITE (Hodis 2016, NEJM, n=643) — oral estradiol started <6 years postmenopause significantly slowed carotid intima thickening; no effect when started >10 years out. KEEPS (Miller 2019): transdermal estradiol for 4 years showed no CV risk signal. WHI re-analysis (Manson 2017, JAMA, 18-year follow-up): for the 50–59 subgroup, all-cause mortality HR 0.69. The NAMS 2022 Position Statement is explicit: "For women <60 yr or <10 yr from menopause, MHT benefits outweigh risks."
SCIENCE + MECHANISM
In 2002, WHI was catastrophically translated by media as "MHT causes cancer," driving an 80% global drop in prescriptions. The problem: WHI's main arm averaged age 63 and used oral conjugated equine estrogens (CEE) + medroxyprogesterone acetate (MPA) — far from current practice. The "timing hypothesis": in healthy young endothelium, estrogen is vasodilatory and antiatherogenic; once plaque exists, estrogen may destabilize it. Transdermal estradiol bypasses hepatic first-pass → no excess VTE risk (vs oral). Micronized progesterone (vs MPA) has a better breast and metabolic profile.
PROTOCOL
ScenarioRegimenNote
Uterus intact + VMSTransdermal E2 patch 0.025–0.05 mg/d + micronized progesterone 100–200 mg PO at bedtimeProgesterone also aids sleep
HysterectomyTransdermal E2 aloneNo progesterone needed
GSM symptoms onlyLocal vaginal estrogen (cream / tablet)Minimal systemic absorption; most guidelines permit even with breast-cancer history
Cannot / will not use MHTFezolinetant 45 mg/d + CBT + resistance trainingNon-hormonal first-line
Contraindications: current / recent breast cancer, undiagnosed vaginal bleeding, active thromboembolism, severe liver disease. Caution: BRCA, strong family history — shared decision-making with oncology.
FEMALE-SPECIFIC + MYTHS
Absolute breast cancer risk increment is tiny: with combined E+P for 5+ years, ~1 extra case per 1000 woman-years — comparable to two glasses of wine daily or BMI >30 (Bluming & Tavris). That number is more useful than the abstract "cancer" label.
Myth 1: "Bioidentical = safer / more natural" — unregulated compounded preparations have uncontrolled dosing; FDA-approved micronized progesterone + transdermal E2 are the actually-bioidentical, evidence-based choice.
Myth 2: "MHT is only for short-term use" — NAMS sets no arbitrary stop date; reassess benefit/risk yearly.
THIS WEEK + REFLECTION
THIS WEEK
Read the first two chapters of Bluming & Tavris's Estrogen Matters, or listen to Peter Attia podcast #210 with Avrum Bluming. Write your "MHT fears" list and check each against the absolute-risk numbers.

Reflection: When an intervention's benefit is "healthspan" (invisible non-decline) and its risk is "events" (visible diagnoses), why do humans systematically undervalue the former?
SUB · Bone / Estrogen
Bone Density — The First 5 Postmenopausal Years
BOTTOM LINE
Plummeting estrogen lets bone resorption outpace formation: ~2%/year loss in the first 5 postmenopausal years, then 1%/year. By age 65, half of women already have low bone mass. Heavy resistance + impact training provides bone stimulus far beyond walking, complemented by calcium, vitamin D, K2, and — when indicated — MHT or bisphosphonates.
EVIDENCE LEVEL
RCT: LIFTMOR (Watson 2018, JBMR, n=101 postmenopausal women with low bone mass): twice-weekly 30-min HiRIT (80–85% 1RM squat/deadlift/overhead press + impact landings) over 8 months produced +2.9% lumbar BMD and +0.3% hip BMD; controls lost on both. Cochrane systematic review (Howe 2011): weight-bearing plus high-intensity resistance is the most effective non-pharmacologic intervention.
SCIENCE + MECHANISM
Bone is dynamic — osteoclasts resorb, osteoblasts build, continuously remodeling. Estrogen restrains osteoclasts via the RANKL/OPG pathway; sudden withdrawal disinhibits resorption, collapsing trabecular bone first (spine, distal radius). Osteocytes sense mechanical loading via sclerostin (SOST); only high strain rates — jump landings, heavy loads — trigger formation. Walking and yoga don't move the needle. DEXA T-score: ≥−1.0 normal, −1.0 to −2.5 osteopenia, ≤−2.5 osteoporosis.
PROTOCOL
• Training (core): 2–3×/week heavy resistance (squat, deadlift, overhead press at 80%+ 1RM, 5×5) + 2×/week impact work (10 jump landings × 3 sets, starting from 10 cm)
• Calcium: food first, 1000–1200 mg/day (200 ml milk ≈ 240 mg; 100 g firm tofu ≈ 150 mg; 50 g sesame ≈ 500 mg). Supplemental Ca >500 mg/day may raise CV risk
• Vitamin D: maintain 25(OH)D at 30–50 ng/mL; most need 1000–2000 IU/day
• Vitamin K2 (MK-7 90–180 μg/d): moderate evidence; synergizes with D to direct calcium to bone rather than vasculature
• Screening: DEXA from age 65; from age 50 with risk factors (early menopause, low BMI, hormonal deprivation, family history)
• Pharmacology: T <−2.5 or prior fragility fracture → bisphosphonate / Denosumab / Romosozumab (anabolic, most potent but time-limited)
FEMALE-SPECIFIC + MYTHS
Athletes with menstrual dysfunction, lactating women, and those with early menopause (<45) lose bone earlier; POI patients should be on MHT to age 51 by default (NAMS). Asian women have lower peak bone mass; 1-year mortality after hip fracture is ~20% — don't wait until 70 to start lifting.
Myth 1: "Walking is enough for bones" — strain rate is too low; almost no osteogenic signal.
Myth 2: "More calcium pills is better" — >1200 mg/d from supplements is associated with CV risk signals; food calcium is safer.
Myth 3: "Yoga prevents fractures" — mobility helps, but certain flexion/twisting poses can raise vertebral fracture risk in those already osteopenic (Sinaki 2005).
THIS WEEK + REFLECTION
THIS WEEK
Do two "mini-LIFTMOR" sessions: 3 sets of squats (bodyweight or loaded, to 2 reps shy of failure) + 3 × 10 jump landings (from a step or in place). Note any knee/back discomfort to baseline next week's load increase.

Reflection: We readily accept "muscle is use-it-or-lose-it" — why do we treat bone as a static structure until the DEXA report finally wakes us up?
SUB · Body composition / Metabolism
Midlife Body Composition — Waist Up, Scale Unchanged
BOTTOM LINE
Perimenopause is not "slowed metabolism" — it's a stealth swap of muscle loss + visceral fat redistribution. The bathroom scale lies; waist circumference, DEXA, and fasting insulin are the real signals.
EVIDENCE LEVEL
Cohort: SWAN body composition sub-study (Greendale 2019, JCI Insight) showed an average 0.2%/year lean-mass loss and 1.7%/year trunk-fat gain across the menopause transition, independent of age and weight change. Pontzer 2021 (Science, n>6400) doubly-labeled water study refuted "midlife metabolic crash" — TDEE is roughly flat between ages 20 and 60. Menopausal change is driven by body composition, not a broken metabolism.
SCIENCE + MECHANISM
Estrogen drop shifts lipoprotein lipase activity toward visceral depots → visceral adipose tissue (VAT) increases. VAT secretes IL-6 and TNF-α and is a key driver of insulin resistance, ApoB elevation, and atherosclerosis. Simultaneously, anabolic resistance rises and protein oxidation increases → accelerated sarcopenia. The familiar complaint: "I didn't eat more, but my waist grew."
PROTOCOL
• Protein floor: 1.6–2.2 g/kg/day, ≥30 g per meal (breakfast especially — most women hit only ~10 g there)
• Strength training: 3×/week compound lifts (squat, deadlift, push/pull), progressive overload — superior to "light weights, high reps"
• Zone 2 + VO2max: 150 min/week Zone 2 + one 4×4 high-intensity interval session
• Measurement: waist circumference (umbilicus) < 80 cm (Asian women); DEXA body composition baseline + annual; fasting insulin <7 μIU/mL, HOMA-IR <1.5
• Don't track: bathroom scale, BMI (most misleading in midlife)
FEMALE-SPECIFIC + MYTHS
"Eating less and still gaining" usually stacks three errors: under-counted liquid calories + inadequate resistance training + insufficient protein. Stacy Sims: midlife women should cut "jogging + dieting" and add "heavy loads + high protein." MHT doesn't directly cause weight loss but reduces visceral redistribution and improves insulin sensitivity (KEEPS sub-study).
Myth 1: "Midlife metabolism is broken" — Pontzer disproves it; the issue is muscle and movement, not BMR.
Myth 2: "Light weights tone, heavy weights bulk" — women's testosterone is far too low for "bulky"; light loads don't provide sufficient stimulus.
Myth 3: "Lose the fat first, then lift" — diet + cardio is the fastest way to lose muscle.
THIS WEEK + REFLECTION
THIS WEEK
Measure waist circumference once this week and log it (phone note). Anchor breakfast with one scoop of whey + 2 whole eggs (~30 g protein). Schedule 2 strength sessions (squat 5×5 + deadlift 3×5). Re-measure waist at week 8 — far more informative than the scale.

Reflection: If the bathroom scale systematically misleads midlife women, why does the medical system still default to BMI? Whose convenience overrides whose accuracy?

📚 Resources

🧠 Reflections

① Why has the misreading of WHI persisted for 20 years?
News cycles reward sensational conclusions; corrective re-analyses rarely make headlines. Gynecology textbooks update slowly. Entrenched interests (antidepressant, sleep-aid markets) filled the gap. It's a classic case of medical communication failure: when a study conclusion doesn't match mechanism or subsequent RCTs, the problem is usually interpretation, not physiology.
② What risk does the MHT decision really trade for what risk?
Not using MHT = accepting certain accelerated bone loss + VMS + the loss of the early cardiovascular window, in exchange for the psychological comfort of "I didn't actively do anything." Using MHT = accepting a small absolute breast-cancer increment in exchange for symptom relief + bone protection + likely CV benefit. Neither is "zero risk." Treating inaction as safe is a default-bias error in decision science.
③ Is high-intensity training too aggressive for perimenopausal women?
The opposite. Low-intensity long-duration cardio combined with under-eating is midlife women's worst combo, accelerating cortisol and muscle loss. LIFTMOR specifically recruited postmenopausal women with low bone mass; loads to 80% 1RM produced no new fractures and improved BMD. The precondition is good technique and progression. "Aggressive" is relative — your body's real signal is that this load is what triggers adaptation.
④ If perimenopause is predictable and controllable, why is it culturally framed as decline?
The "decline" frame lets medicine "not act," workplaces "not adjust," and women "silently endure." Reframing it as "transition + intervention window" funds preventive medicine, HR policy (UK menopause leave), and personal data tracking. Language defines the space of action.
← Back to index